← Back to Clinical Trials
Recruiting NCT07428187

NCT07428187 Snacking Effects on the Brain Response to Foods and Satiety During Dieting

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07428187
Status Recruiting
Phase
Sponsor University of Colorado, Denver
Condition Overweight/Obesity
Study Type INTERVENTIONAL
Enrollment 70 participants
Start Date 2026-03-05
Primary Completion 2028-03-31

Eligibility & Interventions

Sex All sexes
Min Age 25 Years
Max Age 45 Years
Study Type INTERVENTIONAL
Interventions
Snack Type 1: WalnutsSnack Type 2: Pretzels

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 70 participants in total. It began in 2026-03-05 with a primary completion date of 2028-03-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study plans to learn more about how different types of snacks may affect brain processes relating to eating behaviors during a diet intervention.

Eligibility Criteria

Inclusion Criteria: * 25-45 years old * BMI at least 27 kg/m2 * Comfortable completing a weight-loss intervention\\ * Willing to consume a daily snack of either walnuts or pretzels Exclusion Criteria: * Nut or wheat allergy * History of bariatric surgery * Current eating disorder * Current illicit substance use * Current pregnancy, lactation (or less than 3 months after stopping lactation), or less than 6 months postpartum * Uncontrolled hypertension (\>160/100 mmHg) * Significant endocrine/metabolic disease kidney disease, liver disease, or blood disease that would be anticipated to affect study results * Taking injectable medications, sulfonylureas, or meglitinides for diabetes treatment * Taking weight-loss medications, or steroids within \~3 months prior to study participation (e.g., GLP-1 receptor agonists) * Significant mental health changes within \~3 months prior to study participation (e.g., medication adjustments, new psychiatric diagnoses, hospitalization relating to mental health concerns) * Neurological illnesses or injury that would be anticipated to affect MRI data * Weight change greater than 10% within 3 months prior to study participation * Currently participating in another weight-loss study * Not comfortable eating the study-provided meals (with allowances for dietary preferences) and/or following a highly restrictive diet (e.g., vegan) * MRI-specific exclusion criteria (e.g., metal in the body, weight \>500 lbs

Contact & Investigator

Central Contact

Allison Hild, BS

✉ allison.hild@cuanschutz.edu

📞 3037249024

Principal Investigator

Kristina T Legget, PhD

PRINCIPAL INVESTIGATOR

University of Colorado, Denver

Frequently Asked Questions

Who can join the NCT07428187 clinical trial?

This trial is open to participants of all sexes, aged 25 Years or older, up to 45 Years, studying Overweight/Obesity. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07428187 currently recruiting?

Yes, NCT07428187 is actively recruiting participants. Contact the research team at allison.hild@cuanschutz.edu for enrollment information.

Where is the NCT07428187 trial being conducted?

This trial is being conducted at Aurora, United States.

Who is sponsoring the NCT07428187 clinical trial?

NCT07428187 is sponsored by University of Colorado, Denver. The principal investigator is Kristina T Legget, PhD at University of Colorado, Denver. The trial plans to enroll 70 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology